Genprex Overview
Valuation check: GNPX's ROE is -111.51%, below the Healthcare sector average of -100.59%.
Get informed when a big investor buys or sells
+ Follow-111.51%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Genprex (GNPX) currently reports a ROE of -111.51%. That is below the Healthcare sector average of -100.59%. Use the charts on this page to explore Genprex's ROE history and peer comparisons.
Genprex's ROE of -111.51% is lower than the Healthcare sector average of -100.59%. That is roughly 10.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Genprex's current -111.51% should be judged against Healthcare norms (sector average: -100.59%) and against GNPX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -111.51%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -100.59%. From there, open related valuation or income-statement pages for Genprex, and consider following GNPX for alerts when major investors trade the stock.
Genprex is classified in the Healthcare sector. On ROE, it currently shows -111.51% versus a sector average near -100.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GNPX with unrelated industries.
